Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV

Bishnu P. De, Neil R. Hackett, Ronald Crystal, Julie L. Boyer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Achieving both immediate and sustained protection against diseases caused by bacterial toxins and extracellular pathogens is a challenge in developing biodefense therapeutics. We hypothesized that a single co-administration of an adenovirus (Ad) vector and an adeno-associated virus (AAV) vector, both expressing a pathogen-specific monoclonal antibody, would provide rapid, persistent passive immunotherapy against the pathogen. In order to test this strategy, we used the lethal toxin of Bacillus anthracis as a target of a monoclonal antibody directed against the protective antigen (PA) component of the toxin, using co-administration of an Ad vector encoding an anti-PA monoclonal antibody (AdαPA) and an AAV vector encoding an anti-PA monoclonal antibody (AAVrh.10αPA). As early as 1 day after co-administration of AdαPA and AAVrh.10αPA to mice, serum anti-PA antibody levels were detectable, and were sustained through 6 months. Importantly, animals that received both vectors were protected against toxin challenge as early as 1 day after administration and throughout the 6 month duration of the experiment. These data provide a new paradigm of genetic passive immunotherapy by co-administration of Ad and AAV vectors, each encoding a pathogen-specific monoclonal antibody, as an effective approach for both rapid and sustained protection against a bio-terror attack.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalMolecular Therapy
Volume16
Issue number1
DOIs
Publication statusPublished - 1 Jan 2008
Externally publishedYes

Fingerprint

Anthrax
Dependovirus
Adenoviridae
Immunity
Antigens
Monoclonal Antibodies
Passive Immunization
Bacterial Toxins
Antibodies
Serum

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. / De, Bishnu P.; Hackett, Neil R.; Crystal, Ronald; Boyer, Julie L.

In: Molecular Therapy, Vol. 16, No. 1, 01.01.2008, p. 203-209.

Research output: Contribution to journalArticle

De, Bishnu P. ; Hackett, Neil R. ; Crystal, Ronald ; Boyer, Julie L. / Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. In: Molecular Therapy. 2008 ; Vol. 16, No. 1. pp. 203-209.
@article{71136f5b79a2409fb85ccce5b43487e1,
title = "Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV",
abstract = "Achieving both immediate and sustained protection against diseases caused by bacterial toxins and extracellular pathogens is a challenge in developing biodefense therapeutics. We hypothesized that a single co-administration of an adenovirus (Ad) vector and an adeno-associated virus (AAV) vector, both expressing a pathogen-specific monoclonal antibody, would provide rapid, persistent passive immunotherapy against the pathogen. In order to test this strategy, we used the lethal toxin of Bacillus anthracis as a target of a monoclonal antibody directed against the protective antigen (PA) component of the toxin, using co-administration of an Ad vector encoding an anti-PA monoclonal antibody (AdαPA) and an AAV vector encoding an anti-PA monoclonal antibody (AAVrh.10αPA). As early as 1 day after co-administration of AdαPA and AAVrh.10αPA to mice, serum anti-PA antibody levels were detectable, and were sustained through 6 months. Importantly, animals that received both vectors were protected against toxin challenge as early as 1 day after administration and throughout the 6 month duration of the experiment. These data provide a new paradigm of genetic passive immunotherapy by co-administration of Ad and AAV vectors, each encoding a pathogen-specific monoclonal antibody, as an effective approach for both rapid and sustained protection against a bio-terror attack.",
author = "De, {Bishnu P.} and Hackett, {Neil R.} and Ronald Crystal and Boyer, {Julie L.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1038/sj.mt.6300344",
language = "English",
volume = "16",
pages = "203--209",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV

AU - De, Bishnu P.

AU - Hackett, Neil R.

AU - Crystal, Ronald

AU - Boyer, Julie L.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Achieving both immediate and sustained protection against diseases caused by bacterial toxins and extracellular pathogens is a challenge in developing biodefense therapeutics. We hypothesized that a single co-administration of an adenovirus (Ad) vector and an adeno-associated virus (AAV) vector, both expressing a pathogen-specific monoclonal antibody, would provide rapid, persistent passive immunotherapy against the pathogen. In order to test this strategy, we used the lethal toxin of Bacillus anthracis as a target of a monoclonal antibody directed against the protective antigen (PA) component of the toxin, using co-administration of an Ad vector encoding an anti-PA monoclonal antibody (AdαPA) and an AAV vector encoding an anti-PA monoclonal antibody (AAVrh.10αPA). As early as 1 day after co-administration of AdαPA and AAVrh.10αPA to mice, serum anti-PA antibody levels were detectable, and were sustained through 6 months. Importantly, animals that received both vectors were protected against toxin challenge as early as 1 day after administration and throughout the 6 month duration of the experiment. These data provide a new paradigm of genetic passive immunotherapy by co-administration of Ad and AAV vectors, each encoding a pathogen-specific monoclonal antibody, as an effective approach for both rapid and sustained protection against a bio-terror attack.

AB - Achieving both immediate and sustained protection against diseases caused by bacterial toxins and extracellular pathogens is a challenge in developing biodefense therapeutics. We hypothesized that a single co-administration of an adenovirus (Ad) vector and an adeno-associated virus (AAV) vector, both expressing a pathogen-specific monoclonal antibody, would provide rapid, persistent passive immunotherapy against the pathogen. In order to test this strategy, we used the lethal toxin of Bacillus anthracis as a target of a monoclonal antibody directed against the protective antigen (PA) component of the toxin, using co-administration of an Ad vector encoding an anti-PA monoclonal antibody (AdαPA) and an AAV vector encoding an anti-PA monoclonal antibody (AAVrh.10αPA). As early as 1 day after co-administration of AdαPA and AAVrh.10αPA to mice, serum anti-PA antibody levels were detectable, and were sustained through 6 months. Importantly, animals that received both vectors were protected against toxin challenge as early as 1 day after administration and throughout the 6 month duration of the experiment. These data provide a new paradigm of genetic passive immunotherapy by co-administration of Ad and AAV vectors, each encoding a pathogen-specific monoclonal antibody, as an effective approach for both rapid and sustained protection against a bio-terror attack.

UR - http://www.scopus.com/inward/record.url?scp=37549040584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549040584&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300344

DO - 10.1038/sj.mt.6300344

M3 - Article

C2 - 18059375

AN - SCOPUS:37549040584

VL - 16

SP - 203

EP - 209

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -